-
1
-
2Academic Journal
Authors: S. A. Kharuzhyk, E. A. Zhavrid, A. V. Dziuban, E. V. Sukolinskaja, O. A. Kalenik, С. А. Хоружик, Э. А. Жаврид, А. В. Дзюбан, Е. В. Суколинская, О. А. Каленик
Source: Diagnostic radiology and radiotherapy; Том 11, № 1 (2020); 78-92 ; Лучевая диагностика и терапия; Том 11, № 1 (2020); 78-92 ; 2079-5343 ; 10.22328/2079-5343-2020-1
Subject Terms: оценка регрессии опухолей, diffusion-weighted magnetic resonance imaging, positron emission tomography/computed tomography, tumor responsee valuation, диффузионно-взвешенная магнитно-резонансная томография, позитронная эмиссионная томография/компьютерная томография
File Description: application/pdf
Relation: https://radiag.bmoc-spb.ru/jour/article/view/480/384; Cheson B.D., Fisher R.I., Barrington S.F., Cavalli F., Schwartz L.H., Zucca E., Lister T.A. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification // J. Clin. Oncol. 2014. Vol. 32. P. 3059–3068. https://doi.org/10.1200/JCO.2013.54.8800.; Хоружик С.А., Жаврид Э.А., Сачивко Н.В. Сравнение диагностической эффективности рентгеновской компьютерной томографии, магнитно-резонансной томографии и диффузионно-взвешенной магнитно-резонансной томографии при дифференциации остаточных опухолей и образований посттерапевтического характера у пациентов с лимфомами после завершения лечения // Онкогематология. 2016. № 3. С. 40–48. https://doi.org/10.17650/1818-8346-2016-11-3-40-48.; Padhani A.R., Lecouvet F.E., Tunariu N., Koh D.M., De Keyzer F., Collins D.J., Sala E., Schlemmer H.P., Petralia G., Vargas H.A., Fanti S., Tombal H.B., de Bono J. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer // Eur. Urol. 2017. Vol. 71. P. 81–92. https://doi.org/10.1016/j.eururo.2016.05.033.; Lecouvet F.E, Talbot J.N., Messiou C., Bourguet P., Liu Y., de Souza N.M. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group // Eur. J. Cancer. 2014. Vol. 50. P. 2519–2531. https://doi.org/10.1016/j.ejca.2014.07.002.; Dimopoulos M.A., Hillengass J., Usmani S., Zamagni E., Lentzsch S., Davies F.E., Raje N., Sezer O., Zweegman S., Shah J., Badros A., Shimizu K., Moreau P., Chim C.S., Lahuerta J.J., Hou J., Jurczyszyn A., Goldschmidt H., Sonneveld P., Palumbo A., Ludwig H., Cavo M., Barlogie B., Anderson K., Roodman G.D., Rajkumar S.V., Durie B.G., Terpos E. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement // J. Clin. Oncol. 2015. Vol. 33. P. 657–664. https://doi.org/10.1200/JCO.2014.57.9961.; Barnes A., Alonzi R., Blackledge M., Charles-Edwards G., Collins DJ., Cook G., Coutts G., Goh V., Graves M., Kelly C., Koh DM., McCallum H., Miquel M.E., O’Connor J., Padhani A., Pearson R., Priest A., Rockall A., Stirling J., Taylor S., Tunariu N. van der Meulen J., Walls D., Winfield J., Punwani S. UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer // Br. J. Radiol. 2018. Vol. 91. P. 20170577. https://doi.org/10.1259/bjr.20170577.; De Souza N.M., Winfield J.M., Waterton J.C., Weller A., Papoutsaki M.V., Doran S.J., Collins D.J., Fournier L., Sullivan D., Chenevert T., Jackson A., Boss M., Trattnig S., Liu Y. Implementing diffusion-weighted MRI for body imaging in prospective multicenter trials: current considerations and future perspectives // Eur. Radiol. 2018. Vol. 28. P. 1118–1131. https://doi.org/10.1007/s00330-017-4972-z.; Taouli B., Beer A.J., Chenevert T., Collins D., Lehman C., Matos C., Padhani A.R., Rosenkrantz A.B., Shukla-Dave A., Sigmund E., Tanenbaum L., Thoeny H., Thomassin-Naggara I., Barbieri S., CorcueraSolano I., Orton M., Partridge S.C., Koh D.M. Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop // J. Magn. Reson. Imaging. 2016. Vol. 44. P. 521–540. https://doi.org/10.1002/jmri.25196.; Albano D., Patti C., La Grutta L., Agnello F., Grassedonio E., Mulè A., et al. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas // Eur. J. Radiol. 2016. Vol. 85. P. 313–318. https://doi.org/10.1016/j.ejrad.2015.; Maggialetti N., Ferrari C., Minoia C., Asabella A.N., Ficco M., Loseto G., De Tullio G., de Fazio V., Calabrese A., Guarini A., Rubini G., Brunese L. Role of WB-MR/DWIBS compared to 18 F-FDG PET/CT in the therapy response assessment of lymphoma // Radiol. Med. 2016. Vol. 121. P. 132–143. https://doi.org/10.1007/s11547-015-0581-6.; Herrmann K., Queiroz M., Huellner M.W., de Galiza Barbosa F., Buck A., Schaefer N., Stolzman P., Veit-Haibach P. Diagnostic performance of FDGPET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT // BMC Cancer. 2015. Vol. 15. P. 1002. https://doi.org/10.1186/s12885-015-2009-z.; Mayerhoefer M.E., Karanikas G., Kletter K., Prosch H., Kiesewetter B., Skrabs C., Porpaczy E., Weber M., Knogler T., Sillaber C., Jaeger U., Simonitsch-Klupp I., Ubl P., Müllauer L., Dolak W., Lukas J., Raderer M. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18 F-FDGPET/CT-Controlled Prospective Study in 64 Patients // Clin. Cancer Res. 2015. Vol. 21. P. 2506–2513. https://doi.org/10.1158/1078-0432.CCR-14-2454.; Littooij A.S., Kwee T.C., de Keizer B., Bruin M.C., Coma A., Beek F.J., Fijnheer R., Nievelstein R.A. Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study // J. Magn. Reson. Imaging. 2015. Vol. 42. P. 1646–1655. https://doi.org/10.1002/jmri.24938.; Meignan M., Gallamini A., Meignan M., Gallamini A., Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma // Leuk. Lymphoma. 2009. Vol. 50. P. 1257–1260. https://doi.org/10.1080/10428190903040048.; Meignan M., Itti E., Gallamini A., Younes A. FDG PET/CT imaging as a biomarker in lymphoma // Eur. J. Nucl. Med. Mol. Imaging. 2015. Vol. 42. P. 623–633. https://doi.org/10.1007/s00259-014-2973-6.; Barrington S.F., Mikhaeel N.G., Kostakoglu L., Meignan M., Hutchings M., Müeller S.P., Schwartz L.H., Zucca E., Fisher R.I., Trotman J., Hoekstra O.S., Hicks R.J., O’Doherty M.J., Hustinx R., Biggi A., Cheson B.D. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group // J. Clin. Oncol. 2014. Vol. 32. P. 3048–3058.; Tsuji K., Kishi S., Tsuchida T., Yamauchi T., Ikegaya S., Urasaki Y., Fujiwara Y., Ueda T., Okazawa H., Kimura H. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT // J. Magn. Reson. Imaging. 2015. Vol. 41. P. 1601–1607. https://doi.org/10.1002/jmri.24714.; Алгоритмы диагностики и лечения злокачественных новообразований: клинический протокол / Министерство здравоохранения Республики Беларусь. Минск: Профессиональные издания, 2019. 616 с.; Хоружик С.А., Жаврид Э.А., Сачивко Н.В. Диагностическая эффективность диффузионно-взвешенной магнитно-резонансной томографии всего тела при очаговом и диффузном поражении костного мозга у пациентов с лимфомой // Медицинская визуализация. 2017. № 5. C. 66–81. https://doi.org/10.24835/1607-0763-2017-5-66-81.; Hoane B.R., Shields A.F., Porter B.A., Shulman H.M. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging // Blood. 1991. Vol. 78. P. 728–738.; Adams H.J., Kwee T.C., Vermoolen M.A., de Keizer B., de Klerk J.M., Adam J.A., Fijnheer R., Kersten M.J., Stoker J., Nievelstein R.A. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET // Eur. Radiol. 2013. Vol. 23. P. 2271–228. https://doi.org/10.1007/s00330-013-2835-9.; El Khouli R.H., Macura K.J., Barker P.B., Habba M.R., Jacobs M.A., Bluemke D.A. Relationship of temporal resolution to diagnostic performance for dynamic contrast enhanced MRI of the breast // J. Magn. Reson. Imaging. 2009. Vol. 30. P. 999–1004. https://doi.org/10.1002/jmri.21947.; Crewson P.E. Reader agreement studies // Am. J. Roentgenol. 2005. Vol. 184. P. 1391–1397.; Padhani A.R., Koh D.M., Collins D.J. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions // Radiology. 2011. Vol. 261. P. 700–718. https://doi.org/10.1148/radiol.11110474.; Сакович Р.А., Хоружик С.А., Дзюбан А.В., Барановский О.А., Поддубный К.В., Готто С.И., Жаврид Э.А. Интерпретация исследований ФДГ-ПЭТ/КТ всего тела у пациентов с лимфомой после химиотерапии с использованием шкалы Довиль и полуколичественного анализа // Онкологический журнал. 2017. Т. 11, № 3. С. 5–16.; Adams H.J.A, Kwee T.C. Proportion of false-positive follow-up FDG-PET scans in lymphoma: Systematic review and meta-analysis // Crit. Rev. Oncol. Hematol. 2019. Vol. 141. P. 73–81. https://doi.org/10.1016/j.critrevonc.2019.05.010.; Adams H.J., Nievelstein R.A., Kwee T.C. Prognostic value of complete remission status at end-oftreatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis // Br. J. Haematol. 2015. Vol. 170. P. 185–191. https://doi.org/10.1111/bjh.13420.; Хоружик С.А., Жаврид Э.А., Сачивко Н.В. Диффузионно-взвешенная магнитно-резонансная томография с расчетом измеряемого коэффициента диффузии при мониторинге и раннем прогнозировании регрессии опухолевых очагов в процессе химиотерапии лимфом // Медицинская визуализация. 2015. № 5. С. 83–99.; Toledano-Massiah S., Luciani A., Itti E., Zerbib P., Vignaud A., Belhadj K., Baranes L., Haioun C., Lin C., Rahmouni A. Whole-body diffusion-weighted imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma // Radiographics. 2015. Vol. 35. P. 747–764. https://doi.org/10.1148/rg.2015140145.; Younes A., Hilden P., Coiffier B., Hagenbeek A., Salles G., Wilson W. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) // Ann. Oncol. 2017. Vol. 28. P. 1436–1447. https://doi.org/10.1093/annonc/mdx097.; Bernstine H., Domachevsky L., Nidam M., Goldberg N., Abadi-Korek I., Shpilberg O., Groshar D. 18 F-FDG PET/MR imaging of lymphoma nodal target lesions: Comparison of PET standardized uptake value (SUV) with MR apparent diffusion coefficient (ADC) // Medicine (Baltimore). 2018. Vol. 97. e0490. https://doi.org/10.1097/MD.0000000000010490.
-
3Academic Journal
Authors: Grishina E.E., Stepanova E.A., Bogatyrev A.M.
Source: Almanac of Clinical Medicine; Vol 47, No 8 (2019); 712-720 ; Альманах клинической медицины; Vol 47, No 8 (2019); 712-720 ; 2587-9294 ; 2072-0505
Subject Terms: uveal melanoma, liver metastases, diagnostic methods, ultrasound, computed tomography, hybrid diagnostic methods, positron emission tomography / computed tomography, magnetic resonance imaging, hepatotropic contrasts, увеальная меланома, метастазы в печень, диагностика, ультразвуковое исследование, компьютерная томография, гибридные методы диагностики, позитронно-эмиссионная томография / компьютерная томография, магнитно-резонансная томография, гепатотропные контрасты
File Description: application/pdf
Relation: https://almclinmed.ru/jour/article/view/1132/1155; https://almclinmed.ru/jour/article/downloadSuppFile/1132/1643; https://almclinmed.ru/jour/article/view/1132
-
4Academic Journal
Authors: A. A. Odzharova, M. B. Dolgushin, A. M. Mudunov, I. S. Romanov, R. E. Tulin, D. I. Nevzorov, А. А. Оджарова, М. Б. Долгушин, А. М. Мудунов, И. С. Романов, П. Е. Тулин, Д. И. Невзоров
Source: Head and Neck Tumors (HNT); Том 7, № 3 (2017); 103-107 ; Опухоли головы и шеи; Том 7, № 3 (2017); 103-107 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2017-7-3
Subject Terms: сорафениб, positron emission tomography/computed tomography, metabolic tumor volume and total lesion glycolysis, sorafenib, позитронная эмиссионная томография/компьютерная томография, метаболический объем и общий гликолиз опухоли
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/295/292; Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г .В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. Доступно по: http://oncologyassociation.ru/docs/medstat/sostoyznie/2015.pdf. [State of oncological care in Russia in 2015 (morbidity and mortality). Editors: A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI imeni P.A. Hertzena – filial FGBU “NMIRC” Minzdrava Rossii, 2017. (In Russ.) Available at: http://oncology-association.ru/docs/medstat/ sostoyznie/2015.pdf.].; Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214. DOI:10.1089/thy.2009.0110. PMID: 19860577.; Spitzweg C., Bible K.C., Hofbauer L.C., Morris J.C. Advanced radioiodinerefractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol 2014;2(10):830–42. DOI:10.1016/S2213-8587(14)70051-8. PMID: 24898835.; Семенов Д.Ю., Борискова М.Е., Фарафонова У.В. и др. Прогностическое значение экспрессии натрий-йодного симпортера для высокодифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология 2015;11(1):50–8. [Semyonov D.Yu., Boriskova M.E., Farafonova U.V. et al. Prognostic value of sodium-iodide symporter (NIS) in differentiated thyroid cancer. Klinicheskaya i eksperimentalnaya tireoidologiya = Clinical and Еxperimental Тhyroidology 2015;11(1):50–8. (In Russ.)]. DOI:10.14341/ket2015150-58.; Riesco-Eizaguirre G. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13(1):257–69. DOI:10.1677/erc.1.01119.; Zhang Q., Liu S.Z., Zhang Q. et al. MetaAnalyses of Association Between BRAF (V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Cell Physiol Biochem 2016;38(2):763–76. DOI:10.1159/000443032. PMID: 26871894.; Mian C., Barollo S., Pennelli G. et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf.) 2008;68(1):108–16. DOI:10.1111/j.1365-2265.2007.03008.; Lee W., Min H. S., Lee S. M. et al. Relations between pathological markers and radioiodine scan and 18F-FDG PET/ CT findings in papillary thyroid cancer patients with recurrent cervical nodal metastases. Nucl Med Mol Imaging 2015;49(2):127–34. DOI:10.1007/s13139015-0324-6. PMCID: PMC4463869.; Wong K.P., Lang B.H. New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J Thyroid Res 2012;2012:818204. DOI:10.1155/2012/818204.; Haugen B.R., Alexander E.K., Bible K.C. et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1–33. DOI:10.1089/thy.2016.0628. PMID: 28114862.; Schlumberger M., Tahara M., Wirth L.J. et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;23(Suppl.):Abstract LBA6008:5s. DOI:10.1200/jco.2014.32.18.; Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи 2014;3:4–9. [Rumyantsev P.О., Fomin D.K., Rumyantseva U.V. Criteria of the resistance of the high differentiated thyroid gland carcinoma to the active iodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;3:4–9. (In Russ.)]. DOI:10.17650/2222-1468.; Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910–4. PMID: 3572549.; Grunwald F., Kalicke T., Feine U. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547–52. DOI:10.1007/s002590050493.; Salvatori M., Biondi B., Rufini V. Imaging in endocrinology: 18F-FDG PET/CT in differentiated thyroid carcinoma: clinical indications and controversies in the diagnosis and followup of differentiated thyroid cancer. Eur J Endocrinol 2015;173(3):115–30. DOI:10.1530/EJE-15-0066.; Hallett W.A. Quantification in clinical fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2004;25(7):647–50. PMID: 15208490.; Deandreis D., Al-Ghuzlan A., Leboulleux S. et al. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptake) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer 2011;18:159–69. DOI:10.1677/ERC-10-0233.; Rivera M., Tuttle R.M., Ghossein R. Histopathological characterization of radioactive iodine refractory thyroid carcinomas FDG-PET positive thyroid carcinoma. Cancer 2008;113:48–56. DOI:10.1002/cncr.23515.; O J.H., Lodge M.A., Wahl R.L. Practical PERCIST: A Simplified Guide to PETResponse Criteria in Solid Tumors 1.0. Radiology 2016;280(2):576–84. DOI:10.1148/radiol.2016142043. PMID: 26909647.; Vanderhoek M., Perlman S., Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 2012;53:4–11. DOI:10.2967/jnumed.111.093443. PMID: 22213818.; Wahl R., Jacene H., Kasamon Y., Lodge M. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122–50. DOI:10.2967/jnumed.108.057307. PMID: 19403881.; Larson S.M., Erdi Y., Akhurst T. et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PETFDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 1999;2(3):159–71. DOI:10.1016/S1095-0397(99)00016-3. PMID: 14516540.; Kim B.H., Kim S.-J., Kim S. et al. High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med 2015;29(8):721–9. DOI:10.1007/s12149-015-0994-2.; Brose M.S., Nutting C.M., Jarzab B. et al. DECISION Investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, doubleblind, phase 3 trial. Lancet 2014;384:319– 28. DOI:10.1016/S0140-6736(14)604219. PMCID: PMC4366116.; Marotta V., Ramundo V., Camera L. et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol 2013;78:760–7. DOI:10.1111/cen.12057. PMID: 23009688.; Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8. DOI:10.1016/S2213-8587(13)70215-8.; https://ogsh.abvpress.ru/jour/article/view/295
-
5Academic Journal
Authors: РУДЕНКО Д.И., ПОЗДНЯКОВ А.В., СУСЛОВ В.М.
File Description: text/html
-
6Academic Journal
-
7Academic Journal
Authors: Sosnovskii, N. V., Rozengauz, E. V., Shkolnik, М. I., Nesterov, D. V., Сосновский, Н. В., Розенгауз, Е. В., Школьник, М. И., Нестеров, Д. В.
Subject Terms: PROSTATE CANCER, TRANSRECTAL ULTRASOUND, MAGNETIC RESONANCE IMAGING, COMPUTED TOMOGRAPHY, POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY, РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, ТРАНСРЕКТАЛЬНОЕ УЛЬТРАЗВУКОВОЕ ИССЛЕДОВАНИЕ, МАГНИТНО РЕЗОНАНСНАЯ ТОМОГРАФИЯ, КОМПЬЮТЕРНАЯ ТОМОГРАФИЯ, ПОЗИТРОННО-ЭМИССИОННАЯ ТОМОГРАФИЯ/КОМПЬЮТЕРНАЯ ТОМОГРАФИЯ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2016. T. 139, № 6.; http://elib.usma.ru/handle/usma/13664
Availability: http://elib.usma.ru/handle/usma/13664
-
8Academic Journal
Authors: T. M. Geliashvili, A. V. Vazhenin, E. B. Vasil’eva, N. G. Afanas’eva, Т. М. Гелиашвили, А. В. Важенин, Е. Б. Васильева, Н. Г. Афанасьева
Source: Head and Neck Tumors (HNT); Том 5, № 4 (2015); 11-15 ; Опухоли головы и шеи; Том 5, № 4 (2015); 11-15 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2015-5-4
Subject Terms: сцинтиграфия всего тела с I131, lung metastases, chest X-ray, 18fluorodeoxyglucose positron emission tomography / computed tomography, multislice spiral computed tomography of the chest, 131I whole-body scintigraphy, метастазы в легкие, рентгенография органов грудной клетки, позитронная эмиссионная томография / компьютерная томография с 18-фтордезоксиглюкозой, мультиспиральная компьютерная томография грудной клетки
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/180/185; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). М., 2014. [Kaprin А.D., Starinsky V.V., Petrovа G.V. Malignant tumors in Russia in 2012 (morbidity and fatality). Мoscow, 2014. (In Russ.)].; Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11.; Sipos J.A., Mazzaferri E.L. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010;22(6):395–404.; Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295(10): 2164–7.; Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9.; O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010;15(2):146–56.; Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.; Dinneen S.F., Valimaki M.J., Bergstralh E.J. et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80(7):2041–5.; Валдина Е.А. Заболевания щитовидной железы. СПб.: Питер, 2006. [Valdinа Е.А. Thyroid gland diseases. Saint-Petersburg: Piter, 2006. (In Russ.)].; Showalter T.N., Siegel B.A., Moley J.F. et al. Prognostic factors in patients with welldifferentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm 2008;23(5):655–9.; Sampson E., Brierley J.D., Le L.W. et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110(7):1451–6.; Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status. J Endocrinol Invest 1999;22(11 Suppl):3–7.; Casara D., Rubello D., Saladini G. et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables. J Nucl Med 1993;34(10):1626–31.; Schlumberger M.J., Arcangioli O., Piekarski J.D. et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988;29(11):1790–4.; Wang H., Fu H.L., Li J.N. et al. Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer. Clin Imaging 2008;32(1):32–7.; Hooft L., Hoekstra O.S., Devillé W. et al. Diagnostic accuracy of 18Ffluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(8):3779–86.; Khan N., Oriuchi N., Higuchi T. et al. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003;76(910): 690–5.; Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy-Dglucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77(4):1090–4.; https://ogsh.abvpress.ru/jour/article/view/180
-
9Academic Journal
-
10Academic Journal
-
11Academic Journal
Source: Международный неврологический журнал.
File Description: text/html
-
12Academic Journal
Source: Вестник Витебского государственного медицинского университета.
File Description: text/html
-
13Academic Journal
Authors: M. B. Dolgushin, A. A. Odzharova, A. I. Mikhailov, S. V. Shiryaev, P. E. Tulin, D. I. Nevzorov, V. B. Matveev, М. Б. Долгушин, А. А. Оджарова, А. И. Михайлов, С. В. Ширяев, П. Е. Тулин, Д. И. Невзоров, В. Б. Матвеев
Source: Cancer Urology; Том 11, № 2 (2015); 46-54 ; Онкоурология; Том 11, № 2 (2015); 46-54 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-2
Subject Terms: позитронная эмиссионная томография/компьютерная томография, двухэтапное сканирование, рак предстательной железы, 18F-фторхолин, холин, биохимический рецидив, радикальная простатэктомия, two-staged, prostate cancer, 18F-fluorocholine, choline, biochemical recurrence, prostatectomy
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/453/436; Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Под ред. М. И. Давыдова, Е. М. Аксель. Вестник РОНЦ им. Н. Н. Блохина РАМН, 2010. Т. 21.; Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2014.; Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359–86.; Budiharto T., Joniau S., Lerut E. et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011;60:125–30.; Etzioni R., Cha R., Feuer E. J., Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998;148(8):775–85.; Cimitan M., Bortolus R., Morassut S. et al. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med 2006;33(12):1387–98.; Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med1998;39(6):990–5.; Mottet N., Bastian P. J., Bellmunt J. et al. EAU guidelines on prostate cancer. Update April 2014. European Association of Urology. http://www.uroweb.org/guidelines/onlineguidelines/.; Arlen P. M., Bianco F., Dahut W. L. et al. Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008;179(6):2181–5.; Leventis K., Shariat S. F., Slawin K. M. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 2001;219(2):432–9.; Schmid D. T., John H., Zweifel R. et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623–8.; Schmid H. P., McNeal J. E., Stamey T. A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71(6):2031–40.; Sanz G., Rioja J., Zudaire J. et al. PET and prostate cancer. World J Urol 2004;22:351–2.; Karam J. A., Mason R. P., Koeneman K. S. et al. Molecular imaging in prostate cancer. J Cell Biochem 2003;90:473–83.; Turkbey B., Pinto P. A., Mani H. et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection – histopathologic correlation. Radiology 2010;255(1):89–99.; Turkbey B., Mani H., Shah V. et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011;186(5):1818–24.; Selnaes K. M., Heerschap A., Jensen L. R. et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol 2012;47(11):624–33.; Bratan F., Niaf E., Melodelima C. et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 2013;23(7):2019–29.; Hoeks C. M., Schouten M. G., Bomers J. G. et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62(5):902–9.; Puech P., Rouviere O., Renard-Penna R. et al. Prostate Cancer Diagnosis: Multiparametric MR-targeted Biopsy with Cognitive and Transrectal US-MR Fusion Guidance versus Systematic Biopsy- Prospective Multicenter Study. Radiology 2013;268(2):461–9.; Apolo A. B., Pandit-Taskar N., Morris M. J. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008;49:2031–41.; Husarik D. B., Miralbell R., Dubs M. et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:253–63.; Effert P. J., Bares R., Handt S. et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994–8.; Wetter A., Lipponer C., Nensa F. et al. Evaluation of the PET component of simultaneous [18F] choline PET/MRI in prostate cancer: comparison with [18F] choline PET/CT. Eur J Nucl Med Mol Imaging 2014;41(1):79–88.; Wu L. M., Xu J. R., Gu H. Y. et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol 2013;25(4):252–64.; Джужа Д. А. Позитронная эмиссионная томография в онкоурологии. Лучевая диагностика, лучевая терапия 2013;2(3):67–75.; Mease R. C. Radionuclide based imaging of prostate cancer. Curr Top Med Chem 2010;10:1600–16.; Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer – part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61–71.; Emonds K. M., Swinnen J. V., Mortelman s.L., Mottaghy F. M. Molecular imaging of rostate cancer. Methods 2009;48:193–9. 30. Gutman F., Afl alo-Hazan V., Kerrou K. et al. 8F-Choline PET/CT for initial staging of advanced prostate cancer. AJR 2006;187:618–21.; Schillaci O., Calabria F., Tavolozza M., Ciccio C. et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010;31:39–4.; Sutinen E., Nurmi M., Roivainen A. et al. Kinetics of 11C Choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317–24.; Chiti A. The rising PET: the increasing use of choline PET/CT in prostate cancer. Eur J Nucl Med 2011;38:53–54.; Greco C., Cascini O., Tamburini G. et al. Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse? Prostate Cancer and Prostatic Diseases 2008;11:121–8.; Piccardo A., Paparo F., Picazzo R. et al. Value of Fused 18F-Choline-PET/MRI to Evaluate Prostate Cancer Relapse in Patients Showing Biochemical Recurrence after EBRT: Preliminary Results. BioMed Research International 2014. http://www.ncbi.nlm.nih. gov/pmc/articles/PMC4022120/.; Beheshti M., Langsteger W., Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39(6):396–407.; Beheshti M., Imamovic L., Broiger G. et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010;254:925–33.; Tilki D., Reich O., Graser A. et al. 18FFluoroethylcholine PET/CT identifies lymph node etastasis in patients with prostatespecific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013;63:792–6.; Kwee S. A., Wei H., Sesterhenn I. et al. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006; 47(2): 262–9.; O»Brien M. F., Cronin A. M., Fearn P. A. et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27(22):3591–7.; Zeisel S. H. Dietary choline: biochemistry, physiology, and pharmacology. Ann Rev Nutr 1981;1:95–121.; Carolan P., Hunt C., McConnell D. et al. Radiation exposure reduction to PET technologists with the use of an automated dosage infusion system. J Nucl Med 2012;53:2185.; Massaro A., Ferretti A., Secchiero C. et al. Optimising 18F-choline PET/CT acquisition protocol in prostate cancer patients. North Am J Med Sci 2012;4(9):416.; Von Eyben F. E., Kairemo K. Metaanalysis of 11C-choline and 18F-choline PET/CT for management of patients with rostate cancer. Nucl Med Commun 2014;35(3):221–30.; Pinaquy J. B., Clermont–Galleran D., Pasticier G. et al. Comparative effectiveness of [18F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate 2015;75(3):323–31.; Kjölhede H., Ahlgren G., Almquist H. et al. 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 2014;32(4):965–70.; Agarwal N., Sonpavde G., Sternberg C. N. Novel molecular targets for the therapy of castrationresistant prostate cancer. Eur Urol 2012;61:950–60.; Holland-Letz T., Giesel F. L., Kratochwil C., Haufe S. PET imaging with a [68Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013;40:486–95.; Hong H., Zhang Y., Sun J., Cai W. Positron emission tomography imaging of prostate cancer. Amino Acids 2010;39:11–27.; https://oncourology.abvpress.ru/oncur/article/view/453
-
14Academic Journal
-
15Academic Journal
Authors: КАФАРОВ ЭДГАР САБИРОВИЧ, ФЕДОРОВ СЕРГЕЙ ВЛАДИМИРОВИЧ, ЭЛЬЖУРКАЕВА ЛИДИЯ РАИСОВНА, ВАГАБОВ ИСЛАМ УЗГЕНБАЕВИЧ
Subject Terms: ПОЧКА,KIDNEY,ПОЧЕЧНЫЕ ВЕНЫ,RENAL VEINS,МУЛЬТИСПИРАЛЬНАЯ КОМПЬЮТЕРНАЯ ТОМОГРАФИЯ,КОМПЬЮТЕРНАЯ ТОМОГРАФИЯ,АНОМАЛИИ,ANOMALY,MSCT,CT
File Description: text/html
-
16Academic Journal
Authors: ДОЛГУШИН М.Б., ОДЖАРОВА А.А., МИХАЙЛОВ А.И., ШИРЯЕВ С.В., ТУЛИН П.Е., НЕВЗОРОВ Д.И., МАТВЕЕВ В.Б.
File Description: text/html
-
17Academic Journal
Authors: ГЕЛИАШВИЛИ Т.М., ВАЖЕНИН А.В., ВАСИЛЬЕВА Е.Б., АФАНАСЬЕВА Н.Г.
File Description: text/html
-
18Academic Journal
Authors: Ярошевич, А. И., Ядченко, Е. С., Новик, А. В.
Subject Terms: синус-операции эндоскопические, энофтальм, пневматизация, томография компьютерная, гипоплазия врожденная, рентгенология, Республика Беларусь, maxillary sinus, chronic atelectasis of maxillary sinus, endoscopic sinus surgery
Relation: Ярошевич, А. И. Хронический ателектаз верхнечелюстной пазухи у детей по данным оториноларингологического отделения Гомельской областной детской клинической больницы / А. И. Ярошевич, Е. С. Ядченко, А. В. Новик // Оториноларингология. Восточная Европа. - 2022. - Т. 12, № 2. - С. 192-200.; http://elib.gsmu.by/handle/GomSMU/11854
Availability: http://elib.gsmu.by/handle/GomSMU/11854
-
19Academic Journal
Source: Вестник Тамбовского университета. Серия: Естественные и технические науки.
Subject Terms: 0101 mathematics, СУБПОРОГОВОЕ МИКРОИМПУЛЬСНОЕ ЛАЗЕРНОЕ ВОЗДЕЙСТВИЕ,КИСТОЗНЫЙ МАКУЛЯРНЫЙ ОТЕК,ДИФФУЗНОЕ РЕТИНАЛЬНОЕ УТОЛЩЕНИЕ,ЛАЗЕРКОАГУЛЯЦИЯ СЕТЧАТКИ,ОПТИЧЕСКАЯ КОГЕРЕНТНАЯ ТОМОГРАФИЯ,КОМПЬЮТЕРНАЯ МИКРОПЕРИМЕТРИЯ,SUBTHRESHOLD MICROPULSE YELLOW LASER PHOTOCOAGULATION,CYSTOID MACULAR EDEMA,DIFFUSE RETINAL THICKENING,LASER PHOTOCOAGULATION,OPTICAL COHERENCE TOMOGRAPHY,MICROPERIMETRY, 01 natural sciences, 3. Good health
File Description: text/html
-
20Academic Journal
Source: Онкоурология.
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, рак предстательной железы, олигометастазы, позитронно-эмиссионная томография, компьютерная томография, лучевая терапия, спасительная дистанционная лучевая терапия, сальважная лимфаденэктомия, 3. Good health
File Description: text/html
